EGFr and Breast Cancer: 6-Year Follow-Up Study
Author Information
Author(s): S. Nicholson, J. Richard, C. Sainsbury, P. Halcrow, P. Kelly, B. Angus, C. Wright, J. Henry, J.R. Farndon, A.L. Harris
Hypothesis
Can epidermal growth factor receptor (EGFr) expression predict prognosis in operable breast cancer patients, particularly those with node-negative disease?
Conclusion
EGFr expression is a significant marker of poor prognosis in operable breast cancer, especially for patients with node-negative disease.
Supporting Evidence
- EGFr was second only to axillary node status as a prognostic marker for all patients.
- Patients with EGFr positive tumors had a significantly higher rate of recurrence and death.
- In node-negative patients, EGFr was superior to ER in predicting relapse and survival.
- Multivariate analysis showed EGFr was predictive for both relapse-free and overall survival.
Takeaway
This study found that patients with high levels of a specific protein called EGFr in their breast tumors are more likely to have a bad outcome, even if they seem to be in a good group for treatment.
Methodology
Analysis of EGFr and ER expression in tumor samples from 231 patients with operable breast cancer followed for up to 6 years.
Limitations
The study was conducted before the current standards for node sampling were established, which may affect the applicability of the findings.
Participant Demographics
84 patients (36%) were under 50 years of age and 147 (64%) were over 50.
Statistical Information
P-Value
P<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website